Scan to guide tapering of RA treatment
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study uses a special scan to see if patients with rheumatoid arthritis can safely reduce their TNF inhibitor medication. It may help doctors decide when it's okay to taper treatment without causing a flare.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with rheumatoid arthritis according to standard medical criteria.
- You are in remission or have low disease activity, and your rheumatologist thinks tapering your medication might be appropriate.
- You are currently taking a TNF inhibitor (like adalimumab, etanercept, certolizumab, golimumab, or infliximab) at a steady dose for at least 6 months.
- You are between 18 and 80 years old.
- You have not received steroid injections in the past 3 months, and you are not pregnant, breastfeeding, or have severe kidney or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study uses special imaging to look at lymph vessels in people with rheumatoid arthritis (RA). The goal is to better understand changes in the lymph system in early versus long-standing RA and during certain treatments.
This study uses a special “light tracer” medicine with adalimumab to see where inflammation is in the gut (IBD) or joints (RA). If you have active disease, it may help doctors better target treatment by showing inflammation more clearly during scans.
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
This study compares two different schedules for reducing prednisone (a steroid) in people with rheumatoid arthritis who are also taking another standard arthritis medicine. The goal is to find the safest and most effective way to taper off steroids without causing a flare-up.
This study follows people with rheumatoid arthritis (RA) who have achieved remission—meaning their disease is well-controlled—to see how safely doctors can reduce or stop their medications over time. You would be monitored regularly to ensure your RA stays in remission.
This trial tests a new medicine called CIT-013 for people with rheumatoid arthritis. It aims to see if CIT-013 can help reduce joint swelling and pain when added to your current treatment.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.